DUBLIN – Italian gene therapy pioneer Luigi Naldini is one of the co-founders of a new start-up, Genenta Science SpA, a spinout from the San Raffaele Hospital in Milan, which aims to exploit his deep experience in lentiviral vectors in the development of ex vivo engineered autologous cell therapies for cancer.